Copyright STAT
WASHINGTON — The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s National Priority Voucher,” a ticket to speedier reviews of drug candidates aligned with U.S. priorities. The announcement came as the Trump administration announced agreements with Eli Lilly and Novo Nordisk to reduce the prices of popular weight loss drugs — part of a broader effort to show its interest in delivering medications to Americans faster, and at cheaper prices, than in the past. Advertisement
